Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads …
S Branford, R Lawrence, A Grigg, JF Seymour… - Blood, 2008 - Elsevier
A major molecular response (MMR) by 12 or 18 months (m) of standard dose imatinib for
patients (pts) with newly diagnosed chronic phase CML is associated with a low risk of …
patients (pts) with newly diagnosed chronic phase CML is associated with a low risk of …
[HTML][HTML] Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
G Martinelli, I Iacobucci, G Rosti, F Pane, M Amabile… - Annals of oncology, 2006 - Elsevier
Abstract Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for …
D Marin, J Kaeda, R Szydlo, S Saunders, A Fleming… - Leukemia, 2005 - nature.com
We monitored BCR–ABL transcript levels by quantitative real-time PCR in 103 patients
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
[HTML][HTML] Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg+/-IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular …
R Hehlmann, S Jung-Munkwitz, M Lauseker, A Leitner… - Blood, 2009 - Elsevier
Abstract 339 Initial reports that high dose imatinib results in better responses more rapidly
than standard dose imatinib remain controversial. The German CML Study Group therefore …
than standard dose imatinib remain controversial. The German CML Study Group therefore …
[HTML][HTML] What challenges remain in chronic myeloid leukemia research?
AM Carella, S Branford, M Deininger, FX Mahon… - …, 2013 - ncbi.nlm.nih.gov
Editorials and Perspectives haematologica| 2013; 98 (8) 1169 four years. These results
were confirmed in the multicenter STop IMatinib (STIM) study. 14 The initial analysis …
were confirmed in the multicenter STop IMatinib (STIM) study. 14 The initial analysis …
[HTML][HTML] Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS …
JM Goldman, T Hughes, J Radich, S Branford… - Blood, 2005 - Elsevier
Background and methods: The IRIS study initiated in June 2000 compared treating newly
diagnosed CML-CP pts with IM or interferon+ ara-C. Pts who achieved a complete …
diagnosed CML-CP pts with IM or interferon+ ara-C. Pts who achieved a complete …
Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous …
HM Kantarjian, M Talpaz, J Cortes, S O'Brien… - Clinical cancer …, 2003 - AACR
Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
Most patients with de novo chronic myeloid leukemia (CML) achieve good responses to
imatinib, but the rate and degree of molecular response is variable. We assessed the …
imatinib, but the rate and degree of molecular response is variable. We assessed the …
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International …
TP Hughes, A Hochhaus, S Branford… - Blood, The Journal …, 2010 - ashpublications.org
This study examines the prognostic significance of early molecular response using an
expanded dataset in chronic myeloid leukemia patients enrolled in the International …
expanded dataset in chronic myeloid leukemia patients enrolled in the International …
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with a characteristic
hallmark, the Philadelphia (Ph) chromosome, a balanced translocation t (9; 22)(q34; q11. 2) …
hallmark, the Philadelphia (Ph) chromosome, a balanced translocation t (9; 22)(q34; q11. 2) …